https://www.selleckchem.com/products/bms493.html In addition, analytical laboratories in Africa should develop their capacity to detect PFAS and related compounds regularly and routinely. Local hot spots need to be identified, the influence of these hot spots on the PFAS burden in the environment should be investigated, and environmental regulations should be implemented for these hot spots to reduce their environmental impact. Therefore, we recommend a more routine monitoring of PFAS, including new PFAS that are currently used as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) alternatives, which are not regulated and environmentally concerning. Integr Environ Assess Manag 2021;001-7. © 2021 SETAC. Inhibitor formation is the greatest challenge facing persons with haemophilia treated with factor concentrates. The gold standard testing methodologies are the Nijmegen-Bethesda assay (NBA) for FVIII and Bethesda assay (BA) for FIX inhibitors, which are affected by pre-analytical and inter-laboratory variability. To evaluate inhibitor testing methodology and assess correlation between self-reported and actual methodology. Methodology was evaluated using a survey distributed alongside a UK National External Quality Assessment Service Blood Coagulation external quality assurance (EQA) exercise for FVIII and FIX inhibitor testing. Seventy four survey and EQA exercise responses were received (response rate 63.2%), with 50 paired survey/EQA results. 47.1% (33/70) reported using the NBA and 42.9% (30/70) the BA for FVIII inhibitor testing. Review of FVIII inhibitor assay methodology demonstrated discrepancy (self-reported to actual) in 64.3% (BA reporting) and 27.6% (NBA reporting). Pre-analytical heat treatment was used by 32.4%, most commonly 56°C for 30minutes. Assay cut-offs of 0.1-1.0BU/mL were reported. EQA samples (acquired FVIII and congenital FIX) demonstrated titres and coefficients of variation (CV) of 3.1BU/mL (0.7-15.4BU/mL; CV=43%) and 18.0BU/m